Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Transmission of drug-resistant tuberculosis in HIV-endemic settings.

Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A.

Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30537-1. doi: 10.1016/S1473-3099(18)30537-1. [Epub ahead of print] Review.

PMID:
30554996
2.

Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.

Law S, Daftary A, O'Donnell M, Padayatchi N, Calzavara L, Menzies D.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801030. doi: 10.1183/13993003.01030-2018. Print 2019 Jan.

PMID:
30309972
3.

Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal.

Naidoo K, Dookie N, Naidoo K, Yende-Zuma N, Chimukangara B, Bhushan A, Govender D, Gengiah S, Padayatchi N.

Infect Drug Resist. 2018 Sep 5;11:1413-1421. doi: 10.2147/IDR.S150644. eCollection 2018.

4.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
5.

Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.

Yuengling KA, Padayatchi N, Wolf A, Mathema B, Brown T, Horsburgh CR, OʼDonnell MR.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):474-480. doi: 10.1097/QAI.0000000000001833.

PMID:
30212394
6.

Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.

Dookie N, Naidoo K, Padayatchi N.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00574-18. doi: 10.1128/AAC.00574-18. Print 2018 Aug. No abstract available.

PMID:
30054376
7.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

8.

Palliative care for drug-resistant tuberculosis: An urgent call to action.

Govender T, Naidoo S, Padayatchi N, Gwyther L.

S Afr Med J. 2018 Apr 25;108(5):12290. doi: 10.7196/SAMJ.2018.v108i5.13240. No abstract available.

9.

Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.

Perumal R, Abdelghani N, Naidu N, Yende-Zuma N, Dawood H, Naidoo K, Singh N, Padayatchi N.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):536-542. doi: 10.1097/QAI.0000000000001705.

PMID:
29683992
10.

MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.

Loveday M, Wallengren K, Reddy T, Besada D, Brust JCM, Voce A, Desai H, Ngozo J, Radebe Z, Master I, Padayatchi N, Daviaud E.

PLoS One. 2018 Apr 18;13(4):e0196003. doi: 10.1371/journal.pone.0196003. eCollection 2018.

11.

Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.

Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico KR, Friedland G, Orrell C, Padayatchi N, O'Donnell MR.

BMC Infect Dis. 2018 Apr 11;18(1):171. doi: 10.1186/s12879-018-3080-2.

12.

TB epidemiology: where are the young women? Know your tuberculosis epidemic, know your response.

Perumal R, Naidoo K, Padayatchi N.

BMC Public Health. 2018 Mar 27;18(1):417. doi: 10.1186/s12889-018-5362-4.

13.

Training social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa.

Zelnick JR, Seepamore B, Daftary A, Amico KR, Bhengu X, Friedland G, Padayatchi N, Naidoo K, O'Donnell MR.

Public Health Action. 2018 Mar 21;8(1):25-27. doi: 10.5588/pha.17.0114.

14.

Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.

Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K.

J Antimicrob Chemother. 2018 May 1;73(5):1138-1151. doi: 10.1093/jac/dkx506.

15.

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Naidoo A, Ramsuran V, Chirehwa M, Denti P, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ngcapu S, Chaudhry M, Pepper MS, Padayatchi N.

Pharmacogenomics. 2018 Jan;19(1):17-29. doi: 10.2217/pgs-2017-0144. Epub 2017 Dec 6.

16.

Addressing challenges in scaling up TB and HIV treatment integration in rural primary healthcare clinics in South Africa (SUTHI): a cluster randomized controlled trial protocol.

Naidoo K, Gengiah S, Yende-Zuma N, Padayatchi N, Barker P, Nunn A, Subrayen P, Abdool Karim SS.

Implement Sci. 2017 Nov 13;12(1):129. doi: 10.1186/s13012-017-0661-1.

17.

Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: Challenges and implications.

Mahomed S, Naidoo K, Dookie N, Padayatchi N.

Tuberculosis (Edinb). 2017 Dec;107:137-143. doi: 10.1016/j.tube.2017.09.005. Epub 2017 Sep 18. Review.

PMID:
29050762
18.

High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa.

Naidoo K, Hassan-Moosa R, Yende-Zuma N, Govender D, Padayatchi N, Dawood H, Adams RN, Govender A, Chinappa T, Abdool-Karim S, Abdool-Karim Q.

PLoS One. 2017 Sep 13;12(9):e0184124. doi: 10.1371/journal.pone.0184124. eCollection 2017.

19.

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele.

Naidoo A, Naidoo K, Ramsuran V, Reddy M, Padayatchi N.

Pharmgenomics Pers Med. 2017 Aug 23;10:233-234. doi: 10.2147/PGPM.S146787. eCollection 2017. No abstract available.

20.

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N.

J Clin Pharmacol. 2017 Nov;57(11):1369-1386. doi: 10.1002/jcph.968. Epub 2017 Jul 24. Review.

21.

Drug-resistant tuberculosis in patients with minimal symptoms: favourable outcomes in the absence of treatment.

Loveday M, Ramjee A, Osburn G, Master I, Kabera G, Brust JC, Padayatchi N, Warren R, Theron G.

Int J Tuberc Lung Dis. 2017 May 1;21(5):556-563. doi: 10.5588/ijtld.16.0779.

PMID:
28399971
22.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
23.

Elucidating the role of clofazimine for the treatment of tuberculosis.

O'Donnell MR, Padayatchi N, Metcalfe JZ.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):52-57. doi: 10.5588/ijtld.16.0073. Review.

PMID:
28240574
24.

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.

J Antimicrob Chemother. 2017 May 1;72(5):1441-1449. doi: 10.1093/jac/dkx004.

25.

Turning the tide against tuberculosis.

Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O'Donnell MR.

Int J Infect Dis. 2017 Mar;56:6-9. doi: 10.1016/j.ijid.2017.01.012. Epub 2017 Feb 4.

26.
27.

Antibiotic stewardship for drug resistant tuberculosis.

Padayatchi N, Mahomed S, Loveday M, Naidoo K.

Expert Opin Pharmacother. 2016 Oct;17(15):1981-3. doi: 10.1080/14656566.2016.1225724. Epub 2016 Aug 29. No abstract available.

PMID:
27550243
28.

Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.

Padayatchi N, Naidu N, Yende-Zuma N, OʼDonnell MR, Naidoo K, Augustine S, Zumla A, Loveday M.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):e1-7. doi: 10.1097/QAI.0000000000001110.

PMID:
27509173
29.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.

Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O'Donnell MR, Mlisana KP, Wortman J, Birren BW, Grosset J, Earl AM, Pym AS.

Nat Genet. 2016 May;48(5):544-51. doi: 10.1038/ng.3548. Epub 2016 Apr 11.

30.

Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV.

O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G.

Int J Tuberc Lung Dis. 2016 Apr;20(4):430-4. doi: 10.5588/ijtld.15.0360.

31.

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.

Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, Pearson MD, Priest ME, Zeng Q, Padayatchi N, Grosset J, Young SK, Wortman J, Mlisana KP, O'Donnell MR, Birren BW, Bishai WR, Pym AS, Earl AM.

PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.

32.
33.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
34.

Care of the patient with XDR-TB who has failed treatment.

Jacobson KB, Tate M, Eksteen F, Moll A, Padayatchi N, Friedland G, Shenoi S.

Lancet Respir Med. 2015 Apr;3(4):269-70. doi: 10.1016/S2213-2600(15)00109-5. No abstract available.

35.

Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.

OʼDonnell MR, Pillay M, Pillay M, Werner L, Master I, Wolf A, Mathema B, Coovadia YM, Mlisana K, Horsburgh CR, Padayatchi N.

J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):536-43. doi: 10.1097/QAI.0000000000000650.

36.

Surgical treatment of complications of pulmonary tuberculosis, including drug-resistant tuberculosis.

Madansein R, Parida S, Padayatchi N, Singh N, Master I, Naidu K, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:61-7. doi: 10.1016/j.ijid.2015.01.019. Review.

37.

Cellular therapy in tuberculosis.

Parida SK, Madansein R, Singh N, Padayatchi N, Master I, Naidu K, Zumla A, Maeurer M.

Int J Infect Dis. 2015 Mar;32:32-8. doi: 10.1016/j.ijid.2015.01.016. Review.

38.

Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.

Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B, Ngozo J, Master I, Cassell G, Padayatchi N.

Int J Tuberc Lung Dis. 2015 Feb;19(2):163-71. doi: 10.5588/ijtld.14.0369.

39.

The contrasting cultures of HIV and tuberculosis care.

Daftary A, Calzavara L, Padayatchi N.

AIDS. 2015 Jan 2;29(1):1-4. doi: 10.1097/QAD.0000000000000515. No abstract available.

40.

Drug-resistant tuberculosis control in South Africa: scientific advances and health system strengthening are complementary.

Padayatchi N, Loveday M, Naidu N.

Expert Opin Pharmacother. 2014 Oct;15(15):2113-6. doi: 10.1517/14656566.2014.953053.

41.

Malnutrition associated with unfavorable outcome and death among South African MDR-TB and HIV co-infected children.

Hicks RM, Padayatchi N, Shah NS, Wolf A, Werner L, Sunkari VB, O'Donnell MR.

Int J Tuberc Lung Dis. 2014 Sep;18(9):1074-83. doi: 10.5588/ijtld.14.0231.

PMID:
25189555
42.

Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.

Daftary A, Padayatchi N, O'Donnell M.

Glob Public Health. 2014;9(9):1107-16. doi: 10.1080/17441692.2014.934266. Epub 2014 Jul 18.

43.
44.

Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.

Padayatchi N, Gopal M, Naidoo R, Werner L, Naidoo K, Master I, O'Donnell MR.

J Antimicrob Chemother. 2014 Nov;69(11):3103-7. doi: 10.1093/jac/dku235. Epub 2014 Jun 30.

45.

Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.

OʼDonnell MR, Wolf A, Werner L, Horsburgh CR, Padayatchi N.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):22-9. doi: 10.1097/QAI.0000000000000221.

46.

Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: implications for TB programmes.

Loveday M, Padayatchi N, Wallengren K, Roberts J, Brust JC, Ngozo J, Master I, Voce A.

PLoS One. 2014 Apr 9;9(4):e94016. doi: 10.1371/journal.pone.0094016. eCollection 2014.

47.

Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial.

Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G.

Int J Tuberc Lung Dis. 2014 Feb;18(2):147-54. doi: 10.5588/ijtld.13.0627.

48.

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Karim SS.

Antivir Ther. 2014;19(2):161-9. doi: 10.3851/IMP2701. Epub 2013 Oct 31.

49.

The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred?

Loveday M, Padayatchi N, Voce A, Brust J, Wallengren K.

Int J Tuberc Lung Dis. 2013 Oct;17(10 Suppl 1):56-59. doi: 10.5588/ijtld.13.0101.

50.

Health-care workers' perspectives on workplace safety, infection control, and drug-resistant tuberculosis in a high-burden HIV setting.

Zelnick JR, Gibbs A, Loveday M, Padayatchi N, O'Donnell MR.

J Public Health Policy. 2013 Aug;34(3):388-402. doi: 10.1057/jphp.2013.20. Epub 2013 May 30.

Supplemental Content

Loading ...
Support Center